Loading... (0%)

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

30 April 2019

San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) in patients with…

Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

13 February 2019

Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for 3-V Biosciences’ FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40), a first-in-class,…

3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®

16 October 2017

Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class fatty acid synthase (FASN) inhibitors at the upcoming AASLD meeting. Poster #1972 “Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in…

3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA

08 November 2016

Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been selected for a Presidential Poster of Distinction at the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 11th -15th…

3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA

02 November 2015

Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 5-9 in Boston, Massachusetts. Abstract information is as follows: Title: A First-In-Human Study of the…

3-V Biosciences to Present Data at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna

17 September 2015

Menlo Park, California, September 17, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from its ongoing Phase 1 clinical study at the 18th ECCO – 40th ESMO European Cancer Congress to be held September 25-29 in Vienna, Austria. The late-breaking abstract titled “Evidence of…

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

04 August 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, August 12th at 1:55p.m. ET. About 3-V…

3-V Biosciences Provides Clinical Update on TVB-2640 at AACR Metabolism and Cancer Conference

09 June 2015

Menlo Park, California, June 9, 2015: 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, is pleased to announce that new data from its ongoing Phase 1 Study of its lead program (TVB-2640), a first-in-class Fatty Acid Synthase (FASN) inhibitor were presented at the AACR Metabolism…

3-V Biosciences Appoints Rekha Hemrajani as Chief Financial Officer

19 February 2015

Menlo Park, California, February 19, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Rekha Hemrajani has joined the Company as its Chief Financial Officer, SVP of Business and Financial Operations. Ms. Hemrajani, who was formerly the Vice President, Head of Licensing…

3-V Biosciences Announces Closing of $28.5M Financing Round

30 December 2014

Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the closing of its Series D round of financing co-led by NEA, Kleiner Perkins and Rock Springs Capital Management and includes other new investors such as Ally Bridge Group….